Process Analytical Technology (PAT): The 2026 Guide to Tools, Regulations, and Smarter Procurement

Market Drivers-

Increasing demand for quality control and assurance in manufacturing processes

The pharmaceutical and biotech industries face stringent regulatory requirements and the need to ensure product quality and safety. PAT enables real-time monitoring and control, minimizing risks of batch failures and non-compliance.

Regulatory requirements and compliance standards

Regulatory bodies such as the FDA and EMA continue to emphasize PAT for ensuring product quality, process understanding, and continuous improvement — reinforced by newer guidance covered in the Regulatory & Compliance Landscape section below.

Growing focus on process efficiency and cost reduction

Pharmaceutical companies are increasingly seeking ways to optimize manufacturing processes, reduce production costs, and enhance overall operational efficiency. PAT provides valuable insights for process optimization, reducing waste, and maximizing resource utilization.

Advancements in analytical technologies

Continuous advancements in analytical techniques, sensor technologies, and data analytics enable faster and more accurate analysis, enhancing real-time process monitoring and control.

Integration of AI and machine learning in process analysis

The integration of PAT with AI and machine learning allows for the extraction of actionable insights from complex process data, enabling predictive analytics, proactive decision-making, and continuous process improvement — see the dedicated section below.

PAT and Quality by Design (QbD)

Quality by Design (QbD) and process analytical technology are conceptually inseparable in modern pharmaceutical and biopharmaceutical development. QbD establishes a design space — a defined range of input variables and process parameters within which a product consistently meets its quality attributes, as set out in ICH Q8(R2). PAT provides the real-time measurement infrastructure that keeps a process inside that design space during commercial manufacturing.

The practical consequence is a shift in how batch release decisions are made. Under traditional end-of-batch testing, a product is manufactured and then tested; a failed test means a lost batch. Under a PAT-enabled QbD framework, in-process data is continuously collected and used to demonstrate that every unit produced met quality criteria throughout manufacturing — making real-time release testing a regulatory possibility (see the dedicated section below).

Analytical method validation for spectroscopic PAT tools must satisfy ICH Q2(R2) requirements and FDA’s specific expectations for at-line, on-line, and in-line measurement methods.

2026 Regulatory & Compliance Landscape

PAT sits inside a regulatory framework that has expanded significantly since the FDA’s original 2004 guidance. Procurement and quality teams evaluating PAT investments in 2026 should be aware of several recent developments.

USP General Chapter <1037>. The United States Pharmacopeia published a new draft General Chapter, <1037> “Process Analytical Technology – Theory and Practice,” for public comment in May 2025. The chapter covers PAT definitions, instrumentation and chemometrics, life-cycle management of PAT methods (including model recalibration), and the regulatory landscape. Two related Stimuli articles — on the theory of sampling in PAT and on implementing real-time release testing — were published alongside it. This will be the first USP general chapter dedicated specifically to PAT once finalized, giving the industry a harmonized reference standard beyond FDA and ICH guidance.

ICH Q13 (Continuous Manufacturing). ICH Q13, finalized in November 2022, is now implemented across the FDA, EMA, and Japan’s PMDA. It provides harmonized expectations for control strategies, process models, and lifecycle management in continuous manufacturing — an area where PAT is not optional but foundational, since continuous processes cannot rely on end-of-batch testing alone.

FDA’s draft guidance on 21 CFR 211.110. In January 2025, the FDA issued draft guidance on 21 CFR 211.110, the core cGMP requirement for sampling and testing in-process materials. The guidance explicitly discusses how in-line, at-line, and on-line PAT monitoring can satisfy these requirements for both continuous manufacturing conversions and novel process technologies, while cautioning that process models alone — without any in-process testing — are not currently sufficient to meet the regulation, since models “cannot ensure the continued validity of all… underlying assumptions at all times,” particularly during unplanned disturbances.

The AMT Designation Program. Established under Section 506L of the Food and Drug Omnibus Reform Act (FDORA) of 2022 and finalized in FDA guidance in December 2024, the Advanced Manufacturing Technologies Designation Program formalizes a pathway for early, frequent FDA engagement on novel manufacturing technologies, including PAT-enabled control strategies. It effectively replaces the informal Emerging Technology Program with a statutory framework, and FDA issued its first annual Report to Congress on the program in December 2025.

AI in regulatory submissions. On January 14, 2026, the FDA and EMA jointly published ten Guiding Principles of Good AI Practice in Drug Development, covering AI use across the product lifecycle — including manufacturing. While not binding regulation, the principles signal that AI-driven chemometric and predictive-quality models used within PAT programs will face growing expectations around data governance, risk-based validation, and lifecycle management.

What this means for procurement teams: PAT investments made today should be evaluated not just against the 2004 baseline guidance but against this broader, more active regulatory landscape — particularly for organizations pursuing continuous manufacturing or AI-enabled process control.

Applications in Pharmaceutical Manufacturing

PAT technologies find application across virtually every aspect of pharmaceutical development and manufacturing:

Chemical Synthesis and Reaction Monitoring

PAT enables real-time monitoring of chemical reactions, crystallizations, and purification processes. Applications include catalyzed reactions, organometallic chemistry, hydrogenations, alkylations, polymerizations, and fluorinations. Real-time spectroscopic monitoring allows chemists to track reaction progress, detect intermediates, and optimize reaction conditions without sampling delays.

PAT in Biopharmaceutical Manufacturing

Biopharmaceutical manufacturing is one of the fastest-growing application areas for PAT, and the tools and challenges here differ meaningfully from small-molecule solid dosage manufacturing.

Upstream bioprocessing. In cell culture, PAT enables a level of process understanding that periodic manual sampling cannot match. Raman spectroscopy deployed in-line can continuously track glucose consumption and lactate accumulation in a bioreactor, enabling feedback control systems to adjust nutrient feed rates dynamically rather than on a fixed schedule. Published studies have demonstrated that Raman-based glucose feedback control can improve titer and reduce antibody glycation by more than 40% in some CHO cell-line processes. Near-infrared (NIR) probes provide complementary biomass and culture-health data, while capacitance probes and dissolved-oxygen electrodes round out real-time monitoring of cell density and culture conditions — all without breaching the sterile boundary of the bioreactor.

Perfusion manufacturing. In perfusion culture, where steady-state conditions must be maintained over weeks rather than days, continuous PAT monitoring is even more critical: cell-retention devices, bleed rates, and medium-exchange volumes must be tuned to a constantly shifting biological target, and real-time sensor data is the only practical way to maintain the tight control perfusion demands.

Downstream processing. At-line HPLC and other chromatographic analyzers monitor purification-step performance and product concentration, supporting faster release decisions on chromatography and formulation steps.

Implementation considerations specific to biomanufacturing. Chemometric models built for one bioreactor configuration or cell line often don’t transfer directly to a different scale or product without revalidation — a calibration-transfer challenge that is one of the most commonly cited barriers to PAT adoption at commercial biomanufacturing scale, especially in multi-product facilities. Buyers should ask prospective suppliers and CDMO partners directly how they handle model revalidation across scale-up and product changeovers.

Solid Dosage Form Manufacturing

PAT technologies monitor blending uniformity, granulation endpoints, tablet compression parameters, and coating processes. Near-infrared spectroscopy has proven particularly valuable for content uniformity assessment and blend monitoring.

Formulation Development

During formulation development, PAT provides rapid feedback on factors affecting bioavailability, stability, and manufacturability. This accelerates development timelines and reduces the number of experimental batches required.

Real-Time Release Testing (RTRT): How It Works

Real-time release testing is one of PAT’s most commercially significant applications. Under traditional manufacturing, a batch is produced and then tested; a failed test means a lost batch. Under a PAT-enabled quality-by-design framework, in-process data is continuously collected throughout manufacturing and used — together with validated multivariate models — to demonstrate that every unit produced met quality criteria as it was made. ICH Q8(R2) explicitly recognizes PAT as an enabler of the enhanced process understanding that supports RTRT, and regulatory submissions incorporating PAT-derived design-space data can qualify for more flexible post-approval change management — reducing the regulatory burden of future process improvements.

RTRT is not a single technology but an integrated system: validated PAT sensors, chemometric models, a defined design space, and a quality system capable of making automated or semi-automated release decisions based on process data rather than solely on finished-product lab testing. USP’s forthcoming <1037> chapter includes a dedicated Stimuli article on RTRT implementation, reflecting how central this application has become to the PAT value proposition.

AI, Machine Learning, and Digital Twins in PAT

AI and machine learning are increasingly embedded in PAT programs, extending beyond the multivariate statistical models (like PLS and PCA) that have underpinned chemometrics for decades. Current applications include:

• Predictive quality modeling that forecasts critical quality attributes before a batch or lot completes, rather than only monitoring them in real time.
• Automated anomaly detection across high-frequency spectroscopic and sensor data streams that would be impractical to review manually.
• Digital twins — virtual replicas of a bioreactor, unit operation, or full production line that ingest live PAT data to simulate “what if” scenarios before changes are made on the physical line. Digital twins are one of the fastest-growing adjacent categories to PAT, with market estimates projecting substantial growth as biopharmaceutical manufacturers combine digital twins with PAT sensor data for both upstream and downstream process optimization.
• Adaptive process control, where models don’t just flag deviations but adjust process parameters (such as feed rates) automatically within a validated design space.

Regulatory expectations are catching up to this trend. The FDA and EMA’s January 2026 Guiding Principles of Good AI Practice in Drug Development apply across the manufacturing phase and emphasize risk-based validation, robust data governance, and lifecycle management for AI systems used to generate or analyze evidence — a framework that will directly affect how AI-enabled PAT models are documented and defended during inspections. Procurement teams evaluating AI-enabled PAT platforms should ask suppliers how their model validation and change-control processes align with this emerging framework, and should treat cybersecurity of connected sensor/digital-twin infrastructure as a due-diligence item, not an afterthought, given that connected PAT and digital-twin systems expand a facility’s data-security footprint.

SWOT Analysis

Overall, the Processes Analytical Technology market presents both significant opportunities and challenges for suppliers, as this SWOT analysis shows: